Along-term Study of OPC-262 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in
patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate
the efficacy of OPC-262
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.